Live
- Study Reveals Teabags Release Billions of Microplastics and Nanoplastics, Entering Your Body
- Kumbh Mela 2025: Essential Guide to Comfortable and Respectful Attire for Maha Kumbh
- Hyderabad Real Estate Faces Setback: Property Sales Drop 7% Year-on-Year in 2024
- Gnani’s Gen AI Solutions Revolutionising BFSI
- Trump's WHO threat sparks debate on the efficiency of global health governance
- ICC Champions Trophy 2025 Schedule: India vs Pakistan Match Set for February 23 in Dubai
- Champions Trophy 2025: Full Schedule, Match Dates, Venues, Timings, and Updates
- FRAI Urges Government to Provide Technology Platform for Kirana Stores to Stay Competitive
- Not just Gen Z, millennials too: Redditors discuss the wave of pet parenthood embraced by young Indians
- Innovation can expedite the journey to a Smoke-Free future- in focus at Technovation Abu Dhabi
ANTI-TRUST LAWS : US states file 2nd lawsuit accusing Aurobindo Pharma
Drug major Aurobindo Pharma on Tuesday said various US states have filed a second lawsuit accusing it along with other companies in the US generic drug industry
Hyderabad: Drug major Aurobindo Pharma on Tuesday said various US states have filed a second lawsuit accusing it along with other companies in the US generic drug industry for violating anti-trust laws by fixing prices.
"On May 10, 2019, the Attorney General of the State of Connecticut and additional Attorneys' General of various US states filed a second lawsuit in Federal Court similarly alleging that Aurobindo and other companies in the US generic drug industry had violated anti-trust laws by fixing prices and allocating customers (the "Second State AG Action")," the company said in a regulatory filing.
"The Second State AG Action includes additional parties and additional products which were not referenced in the First State AG Action," the filing added.
Aurobindo Pharma said it is currently reviewing the second lawsuit and said, "we expect that we will be filing papers with the Federal Court in due course denying each of the relevant accusations".
The city-based firm said it does not, at this time, anticipate that these matters will have a material impact on the company's operations or business results.
Earlier in December 2016, the first lawsuit (First State AG Action) was filed in Federal Court alleging that Aurobindo and other companies in the US generic drug industry had violated anti-trust laws by fixing prices and allocating customers.
On June 18, 2018, an amended complaint was filed in the First State AG Action.
"Aurobindo has denied all the relevant accusations in the First State AG Action and is vigorously defending against the matter," the company said.
